Donor-specific HLA Antibodies Are Associated with Late Allograft Dysfunction after Pediatric Liver Transplantation

Transplantation

Volumn 99, Issue 7, 2015, Pages 1416-1422

  Wozniak, Laura J ^a   Hickey, Michelle J ^a,b   Venick, Robert S ^a   Vargas, Jorge H ^a   Farmer, Douglas G ^a   Busuttil, Ronald W ^a   McDiarmid, Sue V ^a   Reed, Elaine F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COMPLEMENT COMPONENT C1Q; GAMMA GLUTAMYLTRANSFERASE; HLA ANTIBODY; HLA ANTIGEN CLASS 2; TACROLIMUS; ALLOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN; HLA DQ ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADOLESCENT; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PEDIATRICS; PRIORITY JOURNAL; TREATMENT OUTCOME; ACUTE DISEASE; ADVERSE EFFECTS; AGE; BLOOD; CHI SQUARE DISTRIBUTION; CHILD; CHRONIC DISEASE; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS, AUTOIMMUNE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFANT; MULTIVARIATE ANALYSIS; NEWBORN; ODDS RATIO; PHENOTYPE; PRESCHOOL CHILD; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TRANSPLANTATION TOLERANCE; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; AGE FACTORS; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMPLEMENT C1Q; CROSS-SECTIONAL STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS, AUTOIMMUNE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-DQ ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; ISOANTIBODIES; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; RISK FACTORS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940659394     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000796     Document Type: Article

References (34)

1. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000;69(3):319-326.
2. Girnita AL, Webber SA, Zeevi A. Anti-HLA alloantibodies in pediatric solid organ transplantation. Pediatr Transplant. 2006;10(2):146-153.
3. Kasahara M, Kiuchi T, Takakura K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection. Transplantation. 1999;67(4):568-575.
4. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant. 2011;11(3):500-510.
5. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant. 2011;11(9):1868-1876.
6. Kaneku H, O'Leary JG, Taniguchi M, et al. Donor-specific HLA antibodies of IgG3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl. 2012;18(8):984-992.
7. Fontana M, Moradpour D, Aubert V, et al. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int. 2010;23(8):858-859.
8. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific HLA antibodies in pediatric late liver allografts. Liver Transpl. 2012;18(11):1333-1342.
9. Waki K, Sugawara Y, Mizuta K, et al. Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies. Transplantation. 2013;95(1):177-183.
10. Girnita A, Mazariegos GV, Castellaneta A, et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol. 2010;71(3):274-276.
11. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibodymediated rejection in kidney transplantation. Nat Rev Nephrol. 2012;8 (11):670-678.
12. Tsai EW, Reed EF. MHC class I signaling: new functional perspectives for an old molecule. Tissue Antigens. 2014;83(6):375-381.
13. Valenzuela NM, Hong L, Shen XD, et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant. 2013;13(2):299-311.
14. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol. 2013;190(12):6635-6650.
15. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369 (13):1215-1226.
16. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant. 2012;12(6):1618-1623.
17. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72(10):849-858.
18. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32(1):98-105.
19. Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donorspecific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16(1):12-17.
20. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30(2):158-163.
21. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91(3): 342-347.
22. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007;7 (4):955-963.
23. Pongpaibul A, Venick RS, McDiarmid SV, et al. Histopathology of de novo autoimmune hepatitis. Liver Transpl. 2012;18(7):811-818.
24. Blumberg JM, Gritsch HA, Reed EF, et al. Kidney paired donation in the presence of donor-specific antibodies. Kidney Int. 2013;84(5): 1009-1016.
25. Castillo-Rama M, Sebagh M, Sasatomi E, et al. Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant. 2013;13(11):2966-2977.
26. Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol. 2013;74(11):1478-1485.
27. Peng DM, Law YM, Kemna MS, et al. Donor-specific antibodies: can they predict C4d deposition in pediatric heart recipients Pediatr Transplant. 2013;17(5):429-435.
28. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13(6):1541-1548.
29. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation. 2012;94 (2):172-177.
30. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312-319.
31. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant. 2014;14 (4):867-875.
32. EvansHM, Kelly DA, McKiernan PJ, et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43(5):1109-1117.
33. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157-1167.
34. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibodymediated rejection and nonadherence. Am J Transplant. 2012;12 (2):388-399.